Table 1 Characteristics and outcomes of patients with hematologic malignancies and COVID-19, according to the type of malignancy
Lymphoid malignancies | Myeloid malignancies | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Total | NHL | MM | CLL | HL | ALL | MDS | AML | CML | Ph-MPN | |
Patients | 697 (100) | 187 (27) | 137 (20) | 109 (15) | 33 (5) | 13 (2) | 78 (11) | 61 (9) | 16 (2) | 63 (9) |
Age, years | 72 (60–79) | 70 (58–77) | 73 (65–79) | 73 (60–81) | 59 (45–75) | 45 (37–55) | 80 (71–86) | 65 (52–76) | 61 (48–74) | 75 (66–83) |
Sex* | % shown as proportion of all patients with that malignancy | |||||||||
Female | 277 (40) | 81 (44) | 56 (41) | 39 (36) | 12 (38) | 7 (54) | 27 (35) | 32 (53) | 3 (20) | 20 (32) |
Male | 413 (60) | 104 (56) | 81 (59) | 68 (64) | 20 (62) | 6 (46) | 51 (65) | 28 (47) | 12 (80) | 43 (68) |
Comorbidities, n | 2 (1–3) | 1 (1–2) | 2 (1–3) | 1 (1–3) | 1 (1–3) | 1 (0–1) | 2 (1–3) | 1 (0–2) | 1 (0–3) | 2 (1–3) |
Cardiac disease | 138 (20) | 33 (18) | 30 (22) | 20 (18) | 8 (24) | 1 (8) | 22 (28) | 7 (11) | 3 (13) | 14 (22) |
Pulmonary disease | 90 (13) | 21 (11) | 20 (15) | 16 (15) | 2 (6) | 1 (8) | 14 (18) | 6 (10) | 4 (25) | 6 (10) |
Renal disease | 77 (11) | 11 (6) | 32 (23) | 8 (7) | 4 (12) | 1 (8) | 9 (12) | 22 (36) | 4 (25) | 9 (14) |
Hypertension | 277 (40) | 64 (34) | 63 (46) | 44 (40) | 13 (39) | 2 (15) | 35 (45) | 1 (2) | 2 (13) | 30 (48) |
Diabetes | 121 (17) | 29 (16) | 29 (21) | 20 (18) | 7 (21) | 0 | 18 (23) | 5 (8) | 3 (19) | 10 (16) |
Other cancer | 79 (11) | 19 (10) | 14 (10) | 13 (12) | 1 (3) | 2 (15) | 16 (21) | 2 (3) | 1 (6) | 11 (17) |
Active antineoplastic treatment† | % shown as proportion of all patients with that malignancy | |||||||||
Conventional chemotherapy‡ | 127 (18) | 54(29) | 29 (21) | 2 (2) | 9 (28) | 6 (50) | 1 (1) | 26 (42) | 0 | 0 |
Low-intensity chemotherapy§ | 42 (6) | 1 (1) | 4 (3) | 2 (2) | 0 | 1 (8) | 1 (1) | 0 | 2 (12) | 31 (49) |
Molecular targeted therapies¶ | 82 (12) | 7 (4) | 12 (9) | 28 (26) | 0 | 0 | 0 | 3 (5) | 14 (88) | 18 (29) |
Monoclonal antibodies‡‡ | 44 (6) | 25 (13) | 14 (10) | 1 (1) | 4 (13) | 0 | 0 | 0 | 0 | 0 |
Immunomodulatory drugsǁ | 45 (7) | 0 | 45 (33) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hypomethylating agents** | 33 (5) | 1 (1) | 0 | 0 | 0 | 0 | 15 (19) | 17 (28) | 0 | 0 |
Supportive care†† | 12 (2) | 2 (1) | 0 | 0 | 0 | 0 | 5 (7) | 0 | 0 | 5 (8) |
Not detailed | 24 (3) | 5 (2) | 6 (4) | 1 (1) | 5 (16) | 1 (8) | 2 (3) | 0 | 0 | 4 (6) |
No active therapy | 286 (41) | 92 (49) | 27 (20) | 75 (69) | 14 (44) | 4 (33) | 54 (69) | 15 (25) | 0 | 5 (8) |
Care setting | % shown as proportion of all patients with that malignancy | |||||||||
Ambulatory | 89 (13) | 24 (13) | 16 (12) | 15 (14) | 4 (12) | 3 (23) | 6 (8) | 9 (15) | 6 (37) | 9 (14) |
Hospital | 608 (87) | 163 (87) | 121 (88) | 97 (89) | 29 (88) | 10 (77) | 72 (92) | 52 (85) | 10 (63) | 54 (86) |
Outcome | ||||||||||
Survivors | 467 (67) | 128 (68) | 90 (66) | 70 (64) | 24 (73) | 11 (85) | 45 (58) | 34 (56) | 14 (87) | 51 (81) |
Non-survivors | 230 (33) | 59 (32) | 47 (34) | 39 (36) | 9 (27) | 2 (15) | 33 (42) | 27 (44) | 2 (13) | 12 (19) |